174 related articles for article (PubMed ID: 26893968)
1. Heat shock protein 90 is involved in the regulation of HMGA2-driven growth and epithelial-to-mesenchymal transition of colorectal cancer cells.
Kao CY; Yang PM; Wu MH; Huang CC; Lee YC; Lee KH
PeerJ; 2016; 4():e1683. PubMed ID: 26893968
[TBL] [Abstract][Full Text] [Related]
2. Targeting of multiple oncogenic signaling pathways by Hsp90 inhibitor alone or in combination with berberine for treatment of colorectal cancer.
Su YH; Tang WC; Cheng YW; Sia P; Huang CC; Lee YC; Jiang HY; Wu MH; Lai IL; Lee JW; Lee KH
Biochim Biophys Acta; 2015 Oct; 1853(10 Pt A):2261-72. PubMed ID: 25982393
[TBL] [Abstract][Full Text] [Related]
3. Gene Expression Signature-Based Approach Identifies Antifungal Drug Ciclopirox As a Novel Inhibitor of HMGA2 in Colorectal Cancer.
Huang YM; Cheng CH; Pan SL; Yang PM; Lin DY; Lee KH
Biomolecules; 2019 Nov; 9(11):. PubMed ID: 31684108
[TBL] [Abstract][Full Text] [Related]
4. HSP90 inhibitor NVP-AUY922 enhances TRAIL-induced apoptosis by suppressing the JAK2-STAT3-Mcl-1 signal transduction pathway in colorectal cancer cells.
Lee DH; Sung KS; Bartlett DL; Kwon YT; Lee YJ
Cell Signal; 2015 Feb; 27(2):293-305. PubMed ID: 25446253
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of miR-194 Reverses HMGA2-driven Signatures in Colorectal Cancer.
Chang HY; Ye SP; Pan SL; Kuo TT; Liu BC; Chen YL; Huang TC
Theranostics; 2017; 7(16):3889-3900. PubMed ID: 29109785
[TBL] [Abstract][Full Text] [Related]
6. Radiosensitization of HSF-1 Knockdown Lung Cancer Cells by Low Concentrations of Hsp90 Inhibitor NVP-AUY922.
Kühnel A; Schilling D; Combs SE; Haller B; Schwab M; Multhoff G
Cells; 2019 Sep; 8(10):. PubMed ID: 31569342
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of let-7a-5p predicts lymph node metastasis and prognosis in colorectal cancer: Implications for chemotherapy.
Liu TP; Huang CC; Yeh KT; Ke TW; Wei PL; Yang JR; Cheng YW
Surg Oncol; 2016 Dec; 25(4):429-434. PubMed ID: 27262492
[TBL] [Abstract][Full Text] [Related]
8. HMGA2 promotes intestinal tumorigenesis by facilitating MDM2-mediated ubiquitination and degradation of p53.
Wang Y; Hu L; Wang J; Li X; Sahengbieke S; Wu J; Lai M
J Pathol; 2018 Dec; 246(4):508-518. PubMed ID: 30175854
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional activation of FN1 and IL11 by HMGA2 promotes the malignant behavior of colorectal cancer.
Wu J; Wang Y; Xu X; Cao H; Sahengbieke S; Sheng H; Huang Q; Lai M
Carcinogenesis; 2016 May; 37(5):511-21. PubMed ID: 26964871
[TBL] [Abstract][Full Text] [Related]
10. Antiproliferative effect of the HSP90 inhibitor NVP-AUY922 is determined by the expression of PTEN in esophageal cancer.
Bao XH; Takaoka M; Hao HF; Fukazawa T; Yamatsuji T; Sakurama K; Takigawa N; Nakajima M; Fujiwara T; Naomoto Y
Oncol Rep; 2013 Jan; 29(1):45-50. PubMed ID: 23064324
[TBL] [Abstract][Full Text] [Related]
11. Let-7a inhibits migration, invasion and epithelial-mesenchymal transition by targeting HMGA2 in nasopharyngeal carcinoma.
Wu A; Wu K; Li J; Mo Y; Lin Y; Wang Y; Shen X; Li S; Li L; Yang Z
J Transl Med; 2015 Mar; 13():105. PubMed ID: 25884389
[TBL] [Abstract][Full Text] [Related]
12. Emerging roles for HMGA2 in colorectal cancer.
Wang X; Wang J; Wu J
Transl Oncol; 2021 Jan; 14(1):100894. PubMed ID: 33069103
[TBL] [Abstract][Full Text] [Related]
13. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells.
Walsby EJ; Lazenby M; Pepper CJ; Knapper S; Burnett AK
Br J Haematol; 2013 Apr; 161(1):57-67. PubMed ID: 23356405
[TBL] [Abstract][Full Text] [Related]
14. Reactivation of ERK and Akt confers resistance of mutant BRAF colon cancer cells to the HSP90 inhibitor AUY922.
Wang CY; Guo ST; Wang JY; Yan XG; Farrelly M; Zhang YY; Liu F; Yari H; La T; Lei FX; Jin L; Zhang XD; Jiang CC
Oncotarget; 2016 Aug; 7(31):49597-49610. PubMed ID: 27391062
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake.
Monazzam A; Razifar P; Ide S; Rugaard Jensen M; Josephsson R; Blomqvist C; Langström B; Bergström M
Nucl Med Biol; 2009 Apr; 36(3):335-42. PubMed ID: 19324279
[TBL] [Abstract][Full Text] [Related]
16. HSP90 inhibitor NVP-AUY922 induces cell apoptosis by disruption of the survivin in papillary thyroid carcinoma cells.
Liu J; Sun W; Dong W; Wang Z; Qin Y; Zhang T; Zhang H
Biochem Biophys Res Commun; 2017 May; 487(2):313-319. PubMed ID: 28412368
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effect of novel HSP90 inhibitor NVP-AUY922 against oral squamous cell carcinoma.
Okui T; Shimo T; Hassan NM; Fukazawa T; Kurio N; Takaoka M; Naomoto Y; Sasaki A
Anticancer Res; 2011 Apr; 31(4):1197-204. PubMed ID: 21508365
[TBL] [Abstract][Full Text] [Related]
18. The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells.
Canonici A; Qadir Z; Conlon NT; Collins DM; O'Brien NA; Walsh N; Eustace AJ; O'Donovan N; Crown J
Invest New Drugs; 2018 Aug; 36(4):581-589. PubMed ID: 29396630
[TBL] [Abstract][Full Text] [Related]
19. NVP-AUY922, a novel HSP90 inhibitor, inhibits the progression of malignant pheochromocytoma in vitro and in vivo.
Lian J; Lin D; Xie X; Xu Y; Xu L; Meng L; Zhu Y
Onco Targets Ther; 2017; 10():2219-2226. PubMed ID: 28458565
[TBL] [Abstract][Full Text] [Related]
20. High-mobility-group A2 overexpression provokes a poor prognosis of gastric cancer through the epithelial-mesenchymal transition.
Lee J; Ha S; Jung CK; Lee HH
Int J Oncol; 2015; 46(6):2431-8. PubMed ID: 25845850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
